Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2007, Pages

  Furukawa, Toshi A ^a   Watanabe, N ^b   Churchill, R ^b  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b NONE

Author keywords

Agoraphobia psychology; *therapy ; Antidepressive agents *therapeutic use ; Combined modality therapy methods ; Panic disorder psychology; *therapy ; Psychotherapy *methods ; Randomized controlled trials as topic

Indexed keywords

ALPRAZOLAM; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOMIPRAMINE; FLUVOXAMINE; IMIPRAMINE; LOFEPRAMINE; MOCLOBEMIDE; PAROXETINE; PHENELZINE; PLACEBO; TRAZODONE;

AGORAPHOBIA; ANXIETY; BEHAVIOR THERAPY; BREATHING EXERCISE; CLINICAL TRIAL; COCHRANE LIBRARY; COGNITIVE THERAPY; DATA EXTRACTION; DEPRESSION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; GROUP THERAPY; HUMAN; MEDICAL LITERATURE; MEDLINE; OUTCOME ASSESSMENT; PANIC; PSYCHODYNAMICS; PUBLICATION; RELAXATION TRAINING; REVIEW; SCISEARCH; SOCIAL INTERACTION; TREATMENT OUTCOME;

EID: 34547491316     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004364.pub2     Document Type: Review

References (149)

1. Azhar 2000 {published data only} Azhar MZ. Comparison of fluvoxamine alone, fluvoxamine and cognitive psychotherapy and psychotherapy alone in the treatment of panic disorder in Kelantan - implications for management by family doctors. Medical Journal of Malaysia 2000;55:402-8.
2. Barlow 2000 {published data only} *Barlow DH, Gorman JM, Shear MK, Woods SW. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. JAMA 2000;283:2529-36.
3. Gorman JM, Martinez JM, Goetz R, Huppert JD, Ray S, Barlow DH, et al.The effect of pharmacotherapist characteristics on treatment outcome in panic disorder. Depression and Anxiety 2003;17:88-93.
4. Grilo CM, Money R, Barlow DH, Goddard AW, Gorman JM, Hofmann SG, et al.Pretreatment patient factors predicting attrition from a multicenter randomized controlled treatment study for panic disorder. Comprehensive Psychiatry 1998;39(6):323-32.
5. Hofmann SG, Barlow DH, Papp LA, Detweiler MF, Ray SE, Shear MK, et al.Pretreatment attrition in a comparative treatment outcome study on panic disorder. American Journal of Psychiatry 1998;155(1):43-7.
6. Hofmann SG, Shear MK, Barlow DH, Gorman JM, Hershberger D, Patterson M, et al.Effects of panic disorder treatments on personality disorder characteristics. Depression and Anxiety 1998;8(1):14-20.
7. Huppert JD, Bufka LF, Barlow DH, Gorman JM, Shear MK, Woods SW. Therapists, therapist variables, and cognitive-behavioral therapy outcome in a multicenter trial for panic disorder. Journal of Consulting and Clinical Psychology 2001;69:747-55.
8. Barlow 2000i {published data only} *Barlow DH, Gorman JM, Shear MK, Woods SW. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. JAMA 2000;283:2529-36.
9. Gorman JM, Martinez JM, Goetz R, Huppert JD, Ray S, Barlow DH, et al.The effect of pharmacotherapist characteristics on treatment outcome in panic disorder. Depression and Anxiety 2003;17:88-93.
10. Grilo CM, Money R, Barlow DH, Goddard AW, Gorman JM, Hofmann SG, et al.Pretreatment patient factors predicting attrition from a multicenter randomized controlled treatment study for panic disorder. Comprrehensive Psychiatry 1998;39(6):323-32.
11. Hofmann SG, Barlow DH, Papp LA, Detweiler MF, Ray SE, Shear MK, et al.Pretreatment attrition in a comparative treatment outcome study on panic disorder. American Journal of Psychiatry 1998;155(1):43-7.
12. Hofmann SG, Shear MK, Barlow DH, Gorman JM, Hershberger D, Patterson M, et al.Effects of panic disorder treatments on personality disorder characteristics. Depression and Anxiety 1998;8(1):14-20.
13. Huppert JD, Bufka LF, Barlow DH, Gorman JM, Shear MK, Woods SW. Therapists, therapist variables, and cognitive-behavioral therapy outcome in a multicenter trial for panic disorder. Journal of Consulting and Clinical Psychology 2001;69:747-55.
14. Barlow 2000ii {published data only} Barlow DH, Gorman JM, Shear MK, Woods SW. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. JAMA 2000;283:2529-36.
15. Gorman JM, Martinez JM, Goetz R, Huppert JD, Ray S, Barlow DH, et al.The effect of pharmacotherapist characteristics on treatment outcome in panic disorder. Depression and Anxiety 2003;17:88-93.
16. Grilo CM, Money R, Barlow DH, Goddard AW, Gorman JM, Hofmann SG, et al.Pretreatment patient factors predicting attrition from a multicenter randomized controlled treatment study for panic disorder. Comprehensive Psychiatry 1998;39(6):323-32.
17. Hofmann SG, Barlow DH, Papp LA, Detweiler MF, Ray SE, Shear MK, et al.Pretreatment attrition in a comparative treatment outcome study on panic disorder. American Journal of Psychiatry 1998;155(1):43-7.
18. Hofmann SG, Shear MK, Barlow DH, Gorman JM, Hershberger D, Patterson M, et al.Effects of panic disorder treatments on personality disorder characteristics. Depression and Anxiety 1998;8(1):14-20.
19. Huppert JD, Bufka LF, Barlow DH, Gorman JM, Shear MK, Woods SW. Therapists, therapist variables, and cognitive-behavioral therapy outcome in a multicenter trial for panic disorder. Journal of Consulting and Clinical Psychology 2001;69:747-55.
20. Berger 2004 {published and unpublished data} *Berger P, Sachs G, Amering M, Holzinger A, Bankier B, Katschnig H. Personality disorder and social anxiety predict delayed response in drug and behavioral treatment of panic disorder. Journal of Affective Disorders 2004;80:75-8.
21. Berger P, Sachs G, Amering M, Holzinger A, Maierhofer D, Bankier B, et al.Predictors of treatment-response in panic disorder. 151st Annual Meeting of the American Psychiatric Association. 1998.
22. Katschnig H, Berger P, Sachs G, Amering M, Holzinger A, Maierhofer D, et al.Drugs and psychotherapy in panic disorder: methodological issues. 151st Annual Meeting of the American Psychiatric Association. 1998.
23. de Beurs 1995 {published data only} *de Beurs E, van Balkom AJ, Lange A, Koele P, van Dyck R. Treatment of panic disorder with agoraphobia: comparison of fluvoxamine, placebo, and psychological panic management combined with exposure and of exposure in vivo alone. American Journal of Psychiatry 1995;152:683-91.
24. de Beurs E, van Balkom AJ, Van Dyck R, Lange A. Long-term outcome of pharmacological and psychological treatment for panic disorder with agoraphobia: a 2-year naturalistic follow-up. Acta Psychiatrica Scandinavica 1999;99:59-67.
25. de Beurs E, van Dyck R, Lange A, van Balkom AJ. Perceived upbringing and its relation to treatment outcome in agoraphobia. Clinical Psychology and Psychotherapy 1995;2:78-85.
26. van Balkom AJ, de Beurs E, Koele P, Lange A, van Dyck R. Long-term benzodiazepine use is associated with smaller treatment gain in panic disorder with agoraphobia. Journal of Nervous and Mental Disease 1996;184(2):133-5.
27. van Balkom AJ, de Beurs E, van Dyck R, Lange A. Two-year follow-up after treatment of panic disorder with agoraphobia. 8th European College of Neuropsychopharmacology Congress. 8th European College of Neuropsychopharmacology Congress. 1995.
28. de Beurs 1995i {published data only} *de Beurs E, van Balkom AJ, Lange A, Koele P, van Dyck R. Treatment of panic disorder with agoraphobia: comparison of fluvoxamine, placebo, and psychological panic management combined with exposure and of exposure in vivo alone. American Journal of Psychiatry 1995;152:683-91.
29. de Beurs E, van Balkom AJ, Van Dyck R, Lange A. Long-term outcome of pharmacological and psychological treatment for panic disorder with agoraphobia: a 2-year naturalistic follow-up. Acta Psychiatrica Scandinavica 1999;99:59-67.
30. de Beurs E, van Dyck R, Lange A, van Balkom AJ. Perceived upbringing and its relation to treatment outcome in agoraphobia. Clinical Psychology and Psychotherapy 1995;2:78-85.
31. van Balkom AJ, de Beurs E, Koele P, Lange A, van Dyck R. Long-term benzodiazepine use is associated with smaller treatment gain in panic disorder with agoraphobia. Journal of Nervous and Mental Disease 1996;184(2):133-5.
32. van Balkom AJ, de Beurs E, van Dyck R, Lange A. Two-year follow-up after treatment of panic disorder with agoraphobia. 8th European College of Neuropsychopharmacology Congress. 8th European College of Neuropsychopharmacology Congress. 1995.
33. de Beurs 1995ii {published data only} *de Beurs E, van Balkom AJ, Lange A, Koele P, van Dyck R. Treatment of panic disorder with agoraphobia: comparison of fluvoxamine, placebo, and psychological panic management combined with exposure and of exposure in vivo alone. American Journal of Psychiatry 1995;152:683-91.
34. de Beurs E, van Balkom AJ, Van Dyck R, Lange A. Long-term outcome of pharmacological and psychological treatment for panic disorder with agoraphobia: a 2-year naturalistic follow-up. Acta Psychiatrica Scandinavica 1999;99:59-67.
35. de Beurs E, van Dyck R, Lange A, van Balkom AJ. Perceived upbringing and its relation to treatment outcome in agoraphobia. Clinical Psychology and Psychotherapy 1995;2:78-85.
36. van Balkom AJ, de Beurs E, Koele P, Lange A, van Dyck R. Long-term benzodiazepine use is associated with smaller treatment gain in panic disorder with agoraphobia. Journal of Nervous and Mental Disease 1996;184(2):133-5.
37. van Balkom AJ, de Beurs E, van Dyck R, Lange A. Two-year follow-up after treatment of panic disorder with agoraphobia. 8th European College of Neuropsychopharmacology Congress. 8th European College of Neuropsychopharmacology Congress. 1995.
38. Fahy 1992 {published data only} Fahy TJ, O'Rourke D, Brophy J, Schazmann W, Sciascia S. The Galway Study of Panic Disorder. I: Clomipramine and lofepramine in DSM III-R panic disorder: a placebo controlled trial. Journal of Affective Disorders 1992;25:63-75.
39. O'Rourke D, Fahy TJ, Brophy J, Prescott P. The Galway study of panic disorder III: Outcome at 5 to 6 years. British Journal of Psychiatry 1996;168:462-9.
40. Fava 1997 {published data only} Fava GA, Savron G, Zielezny M, Grandi S, Rafanelli C, Conti S. Overcoming resistance to exposure in panic disorder with agoraphobia. Acta Psychiatrica Scandinavica 1997;95:306-12.
41. Johnston 1995 {published and unpublished data} Johnson DG, Troyer IE, Whitsett SF, Dalby JT. Clomipramine therapy and behavior therapy with agoraphobic women. Canadian Journal of Psychiatry - Revue Canadienne De Psychiatrie 1995;40:192-9.
42. Kampman 2002 {published data only} Kampman M, Keijsers GP, Hoogduin CA, Hendriks GJ. A randomized, double-blind, placebo-controlled study of the effects of adjunctive paroxetine in panic disorder patients unsuccessfully treated with cognitive-behavioral therapy alone. Journal of Clinial Psychiatry 2002;63(9):772-7.
43. Loerch 1999 {published data only} Loerch B, Graf-Morgenstern M, Hautzinger M, Schlegel S, Hain C, Sandmann J, et al.Randomised placebo-controlled trial of moclobemide, cognitive- behavioural therapy and their combination in panic disorder with agoraphobia. British Journal of Psychiatry 1999;174:205-12.
44. Marks 1983 {published data only} Cohen SD, Monteiro W, Marks IM. Two-year follow-up of agoraphobics after exposure and imipramine. British Journal of Psychiatry 1984;144:276-81.
45. Lelliott PT, Marks IM, Monteiro WO, Tsakiris F, Noshirvani H. Agoraphobics 5 years after imipramine and exposure. Outcome and predictors. Journal of Nervous and Mental Disease 1987;175(10):599-605.
46. *Marks IM, Gray S, Cohen D, Hill R, Mawson D, Ramm E, et al.Imipramine and brief therapists-aided exposure in agoraphobics having self-exposure homework. Archives of General Psychiatry 1983;40(2):153-62.
47. Mavissakalian 1983 {published data only} Mavissakalian M, Michelson L, Dealy RS. Pharmacological treatment of agoraphobia: imipramine versus imipramine with programmed practice. British Journal of Psychiatry 1983;143:348-55.
48. Mavissakalian 1986a {published data only} Mavissakalian M. Combined behavioral-therapy and pharmacotherapy of agoraphobia. Journal of Psychiatric Research 1993;27:179-91.
49. Mavissakalian M, Michelson L. Agoraphobia: behavioral and pharmacological treatments, preliminary outcome, and process findings. Psychopharmacology Bulletin 1982;18:91-103.
50. *Mavissakalian M, Michelson L. Agoraphobia: relative and combined effectiveness of therapist-assisted in vivo exposure and imipramine. Journal of Clinical Psychiatry 1986;47:117-22.
51. Mavissakalian M, Michelson L. Self-directed in vivo exposure practice in behavioral and pharmacological treatments of agoraphobia. Behavior Therapy 1983;14:506-19.
52. Mavissakalian M, Michelson L. Two-year follow-up of exposure and imipramine treatment of agoraphobia. American Journal of Psychiatry 1986;143:1106-12.
53. Mavissakalian M, Perel J. Imipramine in the treatment of agoraphobia: dose-response relationships. American Journal of Psychiatry 1985;142:1032-6.
54. Mavissakalian 1986b {published data only} Mavissakalian M. Combined behavioral-therapy and pharmacotherapy of agoraphobia. Journal of Psychiatric Research 1993;27:179-91.
55. Mavissakalian M, Michelson L. Agoraphobia: behavioral and pharmacological treatments, preliminary outcome, and process findings. Psychopharmacology Bulletin 1982;18:91-103.
56. Mavissakalian M, Michelson L. Agoraphobia: relative and combined effectiveness of therapist-assisted in vivo exposure and imipramine. Journal of Clinial Psychiatry 1986;47:117-22.
57. Mavissakalian M, Michelson L. Self-directed in vivo exposure practice in behavioral and pharmacological treatments of agoraphobia. Behavior Therapy 1983;14:506-19.
58. Mavissakalian M, Michelson L. Two-year follow-up of exposure and imipramine treatment of agoraphobia. American Journal of Psychiatry 1986;143:1106-12.
59. Mavissakalian M, Perel J. Imipramine in the treatment of agoraphobia: dose-response relationships. American Journal of Psychiatry 1985;142:1032-6.
60. Oehrberg 1995 {published data only} Oehrberg S, Christiansen PE, Behnke K, Borup AL, Severin B, Soegaard J, et al.Paroxetine in the treatment of panic disorder. A randomised, double- blind, placebo-controlled study. British Journal of Psychiatry 1995;167:374-9.
61. Sharp 1996 {published data only} Sharp DM, Power KG. Predicting treatment outcome for panic disorder and agoraphobia in primary care. Clinical Psychology and Psychotherapy 1999;6(5):336-48.
62. Sharp DM, Power KG. Psychologist, patient, and general practitioneer ratings of outcome of pharmacological and psychological treatments for panic disorder and agoraphobia in primary care. Behavioural and Cognitive Psychotherapy 1998;26:13-27.
63. Sharp DM, Power KG. Treatment-outcome research in panic disorder: Dilemmas in reconciling the demands of pharmacological and psychological methodologies. Journal of Psychopharmacology 1997;11(4):373-80.
64. Sharp DM, Power KG, Simpson RJ, Swanson V, Anstee JA. Global measures of outcome in a controlled comparison of pharmacological and psychological treatment of panic disorder and agoraphobia in primary care. British Journal of General Practice 1997;47(416):150-5.
65. *Sharp DM, Power KG, Simpson RJ, Swanson V, Moodie E, Anstee JA, et al.Fluvoxamine, placebo and cognitive behaviour therapy used alone and in combination in the treatment of ppanic disorder and agoraphobia. Journal of Anxiety Disorders 1996;10:219-42. [MEDLINE: ,].
66. Sharp 1996i {published data only} Sharp DM, Power KG. Predicting treatment outcome for panic disorder and agoraphobia in primary care. Clinical Psychology and Psychotherapy 1999;6(5):336-48.
67. Sharp DM, Power KG. Psychologist, patient, and general practitioneer ratings of outcome of pharmacological and psychological treatments for panic disorder and agoraphobia in primary care. Behavioural and Cognitive Psychotherapy 1998;26:13-27.
68. Sharp DM, Power KG. Treatment-outcome research in panic disorder: Dilemmas in reconciling the demands of pharmacological and psychological methodologies. Journal of Psychopharmacology 1997;11(4):373-80.
69. Sharp DM, Power KG, Simpson RJ, Swanson V, Anstee JA. Global measures of outcome in a controlled comparison of pharmacological and psychological treatment of panic disorder and agoraphobia in primary care. British Journal of General Practice 1997;47(416):150-5.
70. *Sharp DM, Power KG, Simpson RJ, Swanson V, Moodie E, Anstee JA, et al.Fluvoxamine, placebo and cognitive behaviour therapy used alone and in combination in the treatment of ppanic disorder and agoraphobia. Journal of Anxiety Disorders 1996;10:219-42.
71. Sharp 1996ii {published data only} Sharp DM, Power KG. Predicting treatment outcome for panic disorder and agoraphobia in primary care. Clinical Psychology and Psychotherapy 1999;6(5):336-48.
72. Sharp DM, Power KG. Psychologist, patient, and general practitioneer ratings of outcome of pharmacological and psychological treatments for panic disorder and agoraphobia in primary care. Behavioural and Cognitive Psychotherapy 1998;26:13-27.
73. Sharp DM, Power KG. Treatment-outcome research in panic disorder: Dilemmas in reconciling the demands of pharmacological and psychological methodologies. Journal of Psychopharmacology 1997;11(4):373-80.
74. Sharp DM, Power KG, Simpson RJ, Swanson V, Anstee JA. Global measures of outcome in a controlled comparison of pharmacological and psychological treatment of panic disorder and agoraphobia in primary care. British Journal of General Practice 1997;47(416):150-5.
75. *Sharp DM, Power KG, Simpson RJ, Swanson V, Moodie E, Anstee JA, et al.Fluvoxamine, placebo and cognitive behaviour therapy used alone and in combination in the treatment of ppanic disorder and agoraphobia. Journal of Anxiety Disorders 1996;10:219-42.
76. Sheehan 1980a {published data only} *Sheehan DV, Ballanger J, Jacobsen G. Treatment of endogenous anxiety with phobic, hysterical, and hypochondriachal symptoms. Archives of General Psychiatry 1980;37:51-9.
77. Sheehan 1980b {published data only} Sheehan DV, Ballanger J, Jacobsen G. Treatment of endogenous anxiety with phobic, hysterical, and hypochondriachal symptoms. Archives of General Psychiatry 1980;37:51-9.
78. Spinhoven 1996 {published data only} Spinhoven P, Onstein EJ, Klinkhamer RA, der Klein EA. Panic management, trazodone and a combination of both in the treatment of panic disorder. Clinical Psychology and Psychotherapy 1996;3:86-92.
79. Stein 2000 {published data only} Stein MB, Ron Norton G, Walker JR, Chartier MJ, Graham R. Do selective serotonin re-uptake inhibitors enhance the efficacy of very brief cognitive behavioral therapy for panic disorder? A pilot study. Psychiatry Research 2000;94:191-200.
80. Telch 1985 {published data only} Roth WT, Telch MJ, Taylor CB, Agras WS. Autonomic changes after treatment of agoraphobia with panic attacks. Psychiatry Research 1988;24(1):95-107.
81. *Telch MJ, Agras WS, Taylor CB, Roth WT, Gallen CC. Combined pharmacological and behavioral treatment for agoraphobia. Behavior Research and Therapy 1985;23:325-35.
82. Wiborg 1996 {published and unpublished data} Dahl AA, Wiborg IM. Pharmacotherapy and brief dynamic psychotherapy of panic disorder. 9th European College of Neuropsychopharmacology Congress. Amsterdam, The Netherlands: 1996.
83. *Wiborg IM, Dahl AA. Does brief dynamic psychotherapy reduce the relapse rate of panic disorder?. Archives of General Psychiatry 1996;53:689-94.
84. Wiborg IM, Dahl AA. Pharmacotherapy and brief dynamic psychotherapy of panic disorder. Xth World Congress of Psychiatry. Madrid, Spain: 1996.
85. Zitrin 1980 {published data only} Zitrin CM. Differential treatment of phobias: Use of imipramine for panic attacks. Journal of Behavior Therapy and Experimental Psychiatry 1983;14(1):11-8.
86. Zitrin CM, Klein DF, Woerner MG. Treatment of agoraphobia with group exposure in vivo and imipramine. Archives of General Psychiatry 1980;37:63-72.
87. Zitrin 1983 {published data only} Klein DF, Ross DC, Cohen P. Panic and avoidance in agoraphobia. Application of path analysis to treatment studies. Archives of General Psychiatry 1987;44(4):377-85.
88. Klein DF, Zitrin CM, Woerner MG, Ross DC. Treatment of phobias. II. Behavior therapy and supportive psychotherapy: are there any specific ingredients?. Archives of General Psychiatry 1983;40(2):139-45.
89. Lipsitz JD, Mannuzza S, Klein DF, Ross DC, Fyer AJ. Specific phobia 10-16 years after treatment. Depression and Anxiety 1999;10(3):105-11.
90. Zitrin CM. Differential treatment of phobias: Use of imipramine for panic attacks. Journal of Behavior Therapy and Experimental Psychiatry 1983;14(1):11-8.
91. Zitrin CM, Klein DF, Lindemann C, Kaplan JH, Ganz VH. Comparison of short-term treatment regimens in phobic patients: a preliminary report. In: SpitzerRL, KleinDF editor(s). Evaluation of Psychological Therapies. Baltimore, MD: Johns Hopkins Press, 1976:233-250.
92. Zitrin CM, Klein DF, Woerner MG. Behavior therapy, supportive psychotherapy, imipramine, and phobias. Archives of General Psychiatry 1978;35:307-16.
93. *Zitrin CM, Klein DF, Woerner MG, Ross DC. Treatment of phobias. I. Comparison of imipramine hydrochloride and placebo. Archives of General Psychiatry 1983;40:125-38.
94. Zitrin CM, Woerner MG, Klein DF. Differentiation of panic anxiety from anticipatory anxiety and avoidance behavior. In: KleinDF, RabkinJ editor(s). Anxiety: New Research and Changing Concepts. New York, NY: Raven Press, 1981.
95. Agras 1991 *Agras, WS, Telch, MJ, Taylor, CB, Roth, WT, Brouillard, M. Imipramine and exposure therapy in agoraphobia: untangling the actions and interactions. Telch and Lucas (1984).
96. Ba 1999 Ba G, Vigano C. Integrated therapy of panic disorder: a controlled study. 152nd Annual Meeting of the American Psychiatric Association. Washington DC, USA: 1999.
97. Ba G, Vigano C. Integrated therapy of panic disorders: a controlled study. Unpublished manuscript.
98. Vigano C, Bielli A, Carozzi A, Divino T, Pagliarulo E, Ba G. Panic disorder: A two-year follow-up of an integrated treatment approach [Il disturbo di panico: follow up a due anni di un modello di trattamento integrato]. Italian Journal of Psychopathology in press.
99. Chambless 1979 *Chambless DL, Foa EB, Groves GA, Goldstein AJ. Exposure and communications training in the treatment of agoraphobia. Behavior Research and Therapy 1982;20:219-31.
100. Chambless DL, Foa EB, Groves GA, Goldstein AJ. Flooding with Brevital in the treatment of agoraphobia: counter effective?. Behavior Research and Therapy 1979;17(3):243-51.
101. Cox 1988 Cox DJ, Ballanger JC, Laraia M, Hobbs WR, Peterson GA, Hucek A. Different rates of improvement of different symptoms in combined pharmacological and behavioral treatment of agoraphobia. Journal of Behavior Therapy and Experimental Psychiatry 1988;19(2):119-26.
102. Lipsedge 1973 *Lipsedge, MS, Hajioff, J, Huggins, P, Napier, L, Pearce, J, Pike, et al.The management of severe agoraphobia: a comparison of ipronizaid and systematic desensitization. Psychopharmacologia 1973;32(1):67-80.
103. Solyom 1981 *Solyom, C, Solyom, L, LaPierre, Y, Pecknold, J, Morton, L. Phenelzine and exposure in the treatment of phobias. Biological Psychiatry 1981;16(3):239-47.
104. APA 1998 American Psychiatric Association. Practice guideline for the treatment of patients with panic disorder. American Journal of Psychiatry 1998;155 Supplement:1-34.
105. Brown 1995 Brown, TA, Barlow, DH. Long-term outcome in cognitive-behavioral treatment of panic disorder: clinical predictors and alternative strategies for assessment. Journal of Consulting and Clinical Psychology 1995;63:754-65.
106. Bucher 1997 Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. Journal of Clinical Epidemiology 1997;50(6):683-91.
107. Burns 1986 Burns, LE, Thorpe, CL, Cavallaro, LA. Agoraphobia 8 years after behavioral treatment: a follow-up study with interview, self-report, and behavioral data. Behavior Therapy 1986;17:580-91.
108. Carlbring 2002 Carlbring, P, Gustafsson, H, Ekselius, L, Andersson, G. 12-month prevalence of panic disorder with or without agoraphobia in the Swedish general population. Social Psychiatry and Psychiatric Epidemiology 2002;37:207-11.
109. Chalmers 1983 Chalmers TC, Celano P, Sacks HS, Smith H Jr. Bias in treatment assignment in controlled clinical trials. New England Journal of Medicine 1983;309:1358-61.
110. Clark 1990 Calrk DB, Taylor CB, Roth WT, Hayward C, Ahlers A, Margraf J, et al.Surreptitious drug use by patients in a panic disorder study. American Journal of Psychiatry 1990;147:507-9.
111. Clum 1993 Clum GA, Clum GA, Surls R. A meta-analysis of treatments for panic disorder. Journal of Consulting and Clinical Psychology 1993;61:317-26.
112. Coldiz 1989 Coldiz, GA, Miller, JN, Mosteller, F. How study design affects outcomes in comparisons of therapy. I: medical. Statistics in Medicine 1989;9:441-54.
113. Egger 2003 Egger M, Juni P, Bartlett C, Holenstein F, Sterne J.How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study. Health Technology Assessment 2003;7(1):1-76.
114. Fava 2001 Fava, GA, Rafanelli, C, Grandi, S, Conti, S, Ruini, C, Mangelli, L, et al.Long-term outcome of panic disorder with agoraphobia treated by exposure. Psychological Medicine 2001;31:891-8.
115. Foa 2002 Foa EB, Franklin ME, Moser J. Context in the clinic: How well do cognitive-behavioral therapies and medications work in combination?. Biological Psychiatry 2002;52:987-97.
116. Furukawa 2002 Furukawa TA, Guyatt GH, Grifitth LE. Can we individualize the Number Needed to Treat (NNT)? An empirical study of summary effect measures in meta-analyses. International Journal of Epidemiology 2002;31:72-6.
117. Furukawa 2005 Furukawa T, Cipriani A, Barbui C, Brambilla P, Watanabe N. Imputing response rates from means and standard deviations in meta-analysis. International Clinical Psychopharmacology 2005;20(1):49-52.
118. Furukawa 2006 Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59:7-10.
119. Goisman 1995 Goisman RM, Warshaw MG, Steketee GS, Fierman EJ, Rogers MP, Goldenberg I, et al.DSM-IV and the disappearnace of agoraphobia without history of panic disorder: new data on a controversial diagnosis. American Journal of Psychiatry 1995;152:1438-43.
120. Gould 1995 Gould RA, Otto MW, Pollack MH. A meta-analysis of treatment outcome for panic disorder. Clinical Psychology Review 1995;15:819-44.
121. Higgins 2003 Higgins, JP, Thompson, SG, Deeks, JJ, Altman, DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557- 60.
122. Hollon 1981 Hollon, SD, DeRubeis, RJ. Placebo-psychotherapy combinations: inappropriate representations of psychotherapy in drug-psychotherapy comparative trials. Psychological Bulletin 1981;90:467-77.
123. Kessler 2006 Kessler RC, Chiu WT, Jin R, Ruscio AM, Shear K, Walters EE. The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Archives of General Psychiatry 2006;63:415-24.
124. Klein 2000 Klein DF. Flawed meta-analyses comparing psychotherapy with pharmacotherapy. American Journal of Psychiatry 2000;157: 1204-11.
125. Marshall 2000 Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
126. Mattick 1990 Mattick RP, Andrews G, Hadzi-Pavlovic D, Christensen H. Treatment of panic and agoraphobia: an integrative review. Journal of Nervous and Mental Disease 1990;178:567-76.
127. Mavissakalian 1993 Mavissakalian M. Combined behavioral therapy and pharmacotherapy of agoraphobia. Journal of Psychiatric Research 1993;27 Suppl 1:179-91.
128. Mavissakalian 2002 Mavissakalian MR, Perel JM. Duration of imipramine therapy and relapse in panic disorder with agoraphobia. Journal of Clinical Psychopharmacology 2002;22:294-9.
129. Moher 1998 Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al.Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352:609-13.
130. Nathan 2002 Nathan PE, Gorman JM. A Guide to Treatments that Work. 2nd Edition. Oxford: Oxford University Press, 2002.
131. Otto 1996 Otto MW, Pollack MH, Sabatino SA. Maintenance of remission following cognitive behavior therapy for panic disorder: possible deleterious effects of concurrent medication treatment. Behavior Therapy 1996;27:473-82.
132. Otto 2000 Otto MW, Pollack MH, Maki KM. Empirically supported treatments for panic disorder: costs, benefits, and stepped care. Journal of Consulting and Clinical Psychology 2000;68:556-63.
133. Oxman 1992 Oxman AD, Guyatt GH. A consumer's guide to subgroup analyses. Annals of Internal Medicine 1992;116:78-84.
134. Pecknold 1988 Pecknold JC, Swinson RP, Kuch K, Lewis CP. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. III. Discontinuation effects. Archives of General Psychiatry 1988;45:429-36.
135. Pollack 2003 Pollack MH, Allgulander C, Bandelow B, Cassano GB, Greist JH, Hollander E, et al. WCA recommendations for the long-term treatment of panic disorder. CNS Spectrums 2003;8:17-30.
136. Schmidt 1999 Schmidt NB. Panic disorder: cognitive behavioral and pharmacological treatment strategies. Journal of Clinical Psychology in Medical Settings 1999;6:89-111.
137. Schmidt 2001 Schmidt NB, Koselka M, Woolaway-Bickel K. Combined treatments for phobic anxiety disorders. In: Sammons, MT, Schmidt, NB editor (s). Combined Treatments for Mental Disorders: A Guide to Psychological and Pharmacological Interventions. Washington, DC: American Psychological Association, 2001:81-110.
138. Schulz 1995 Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
139. Simon 2002 Simon NM, Safren SA, Otto MW, Sharma SG, Lanka GD, Pollack MH. Longitudinal outcome with pharmacotherapy in a naturalistic study of panic disorder. Journal of Affective Disorders 2002;69:201-8.
140. Song 2003 Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003; 326(7387):472.
141. Taylor 2000 Taylor S. Understanding and Treating Panic Disorder. Chichester: John Wiley & Sons, 2000.
142. Telch 1994 Telch MJ, Lucas R. A. Combined pharmacological and psychological tretment of panic disorder: Current status and future directions. In: WolfeBE, MaserJD editor(s). Treatment of Panic Disorder: A Consensus Development Conference. Washington, DC: American Psychiatric Press, Inc, 1994:177-97.
143. Toni 2000 Toni, C, Perugi, G, Frare, F, Mata, B, Vitale, B, Mengali, F, et al.A prospective naturalistic study of 326 panic-agoraphobic patients treated with antidepressants. Pharmacopsychiatry 2000;33:121-31.
144. van Balkom 1996 van Balkom AJ, de Beurs E, Koele P, Lange A, van Dyck R. Long-term benzodiazepine use is associated with smaller treatment gain in panic disorder with agoraphobia. Journal of Nervous and Mental Disease 1996;184(2):133-5.
145. van Balkom 1997 van Balkom AJ, Bakker A, Spinhoven P, Blaauw BM, Smeenk S, Ruesink B. A meta-analysis of the treatment of panic disorder with or without agoraphobia: a comparison of psychopharmacological, cognitive- behavioral, and combination treatments. Journal of Nervous and Mental Disease 1997;185:510-6.
146. Watanabe 2005 Watanabe N, Churchill R, Furukawa TA. Combined psychotherapy plus benzodiazepines for panic disorder with or without agoraphobia [Protocol]. Cochrane Database of Systematic Reviews 2005, Issue 1.
147. Weissman 1997 Weissman MM, Bland RC, Canino GJ, Faravelli C, Greenwald S, Hwu HG, et al.The cross-national epidemiology of panic disorder. Archives of General Psychiatry 1997;54:305-9.
148. Westra 1998 Westra HA, Stewart SH. Cognitive behavioural therapy
149. WHO 2004 World Health Report 2004. WHO.